Rocket Lab USA, Inc. Contingent consideration fair value adjustments increased by 101.8% to $187.00K in Q1 2026 compared to the prior quarter.
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $2.50M | -$2.50M | $200.00K | -$200.00K | $300.00K | $1.30M | $205.00K | -$271.00K | $0.00 | $0.00 | $0.00 | -$10.62M | $187.00K |
| QoQ Change | — | — | -200.0% | +108.0% | -200.0% | +250.0% | +333.3% | -84.2% | -232.2% | +100.0% | — | — | — | +101.8% |
| YoY Change | — | — | — | — | — | -88.0% | +152.0% | +202.5% | -190.3% | +100.0% | — | — | — | — |